Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.
An experimental once-weekly diabetes medication shows strong blood-sugar control in early human trials without severe side effects, advancing toward larger Phase 3 testing.
In a randomized double-blind phase 1b/2a trial (n=72), once-weekly GZR18 achieved significant HbA1c reductions vs placebo in Chinese T2DM patients (up to -1.81% at higher doses) with an acceptable safety profile — no severe hypoglycemia or serious drug-related adverse events — supporting advancement to phase 3 evaluation as a new long-acting GLP-1 RA.
What the study was
- Study design
- Randomized, double-blind, placebo-controlled phase 1b/2a trial
- Population
- Chinese adults with type 2 diabetes mellitus
- Sample size
- 72
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Cell Reports Medicine
Why it surfaced
Novel long-acting GLP-1 analog with strong HbA1c reduction in phase 1b/2a RCT; Gan & Lee Pharmaceuticals (major Chinese pharma). Limited by small n=72 and phase 1b/2a scope.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.